Literature DB >> 32829666

Effects of Intensive Versus Standard Office-Based Hypertension Treatment Strategy on White-Coat Effect and Masked Uncontrolled Hypertension: From the SPRINT ABPM Ancillary Study.

Lama Ghazi1, Laura P Cohen2, Paul Muntner3, Daichi Shimbo2, Paul E Drawz1.   

Abstract

Guidelines recommend using out-of-office blood pressure (BP) measurements to confirm the diagnoses of hypertension and in the titration of antihypertensive medication. The prevalence of out-of-office BP phenotypes for an office systolic/diastolic BP goal <140/90 mm Hg has been reported. However, the prevalence of these phenotypes when targeting an office systolic/diastolic BP goal <120/80 is unknown. The SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory BP Ancillary study evaluated out-of-office BP using ambulatory BP monitoring in 897 participants 27 months after randomization to intensive versus standard BP targets (office systolic BP <120 versus <140 mm Hg). We used office and daytime BP to assess the proportion of participants with white-coat effect (standard target: office BP ≥140/90 mm Hg and daytime BP <135/85 mm Hg versus intensive target: office BP ≥120/80 mm Hg and daytime BP <120/80 mm Hg) and masked uncontrolled hypertension (standard target: office BP <140/90 mm Hg and daytime BP ≥135/85 mm Hg versus intensive target: office BP <120/80 mm Hg and daytime BP ≥120/80 mm Hg) in each treatment arm. The prevalence of white-coat effect and masked uncontrolled hypertension was 9% and 34%, in both treatment groups. Among participants with uncontrolled office BP, white-coat effect was present in 20% and 23% in the intensive and standard groups, respectively. Among participants with controlled office BP, masked uncontrolled hypertension was present in 62% and 56% in the intensive and standard groups, respectively. In conclusion, a more intensive BP target resulted in a similar proportion of patients with white-coat effect and masked uncontrolled hypertension compared with a standard target.

Entities:  

Keywords:  blood pressure; goals; guideline; phenotype; prevalence

Mesh:

Substances:

Year:  2020        PMID: 32829666      PMCID: PMC7484232          DOI: 10.1161/HYPERTENSIONAHA.120.15300

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  21 in total

1.  Validation of the Omron HEM-907 device for blood pressure measurement.

Authors:  Mohamed A El Assaad; Jirar A Topouchian; Bernadette M Darné; Roland G Asmar
Journal:  Blood Press Monit       Date:  2002-08       Impact factor: 1.444

2.  Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage.

Authors:  Paul E Drawz; Arnold B Alper; Amanda H Anderson; Carolyn S Brecklin; Jeanne Charleston; Jing Chen; Rajat Deo; Michael J Fischer; Jiang He; Chi-Yuan Hsu; Yonghong Huan; Martin G Keane; John W Kusek; Gail K Makos; Edgar R Miller; Elsayed Z Soliman; Susan P Steigerwalt; Jonathan J Taliercio; Raymond R Townsend; Matthew R Weir; Jackson T Wright; Dawei Xie; Mahboob Rahman
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-18       Impact factor: 8.237

3.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Circulation       Date:  2018-10-23       Impact factor: 29.690

Review 4.  Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research: JACC Scientific Expert Panel.

Authors:  Paul Muntner; Paula T Einhorn; William C Cushman; Paul K Whelton; Natalie A Bello; Paul E Drawz; Beverly B Green; Daniel W Jones; Stephen P Juraschek; Karen L Margolis; Edgar R Miller; Ann Marie Navar; Yechiam Ostchega; Michael K Rakotz; Bernard Rosner; Joseph E Schwartz; Daichi Shimbo; George S Stergiou; Raymond R Townsend; Jeff D Williamson; Jackson T Wright; Lawrence J Appel
Journal:  J Am Coll Cardiol       Date:  2019-01-29       Impact factor: 24.094

5.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT).

Authors:  Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

6.  Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD.

Authors:  Francis B Gabbai; Mahboob Rahman; Bo Hu; Lawrence J Appel; Jeanne Charleston; Gabriel Contreras; Marquetta L Faulkner; Leena Hiremath; Kenneth A Jamerson; Janice P Lea; Michael S Lipkowitz; Velvie A Pogue; Stephen G Rostand; Miroslaw J Smogorzewski; Jackson T Wright; Tom Greene; Jennifer Gassman; Xuelei Wang; Robert A Phillips
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-30       Impact factor: 8.237

7.  Effect of long-term antihypertensive treatment on white-coat hypertension.

Authors:  Giuseppe Mancia; Rita Facchetti; Gianfranco Parati; Alberto Zanchetti
Journal:  Hypertension       Date:  2014-09-22       Impact factor: 10.190

8.  Validation of the Omron M5-I, R5-I and HEM-907 automated blood pressure monitors in elderly individuals according to the International Protocol of the European Society of Hypertension.

Authors:  Stefano Omboni; Isabella Riva; Alessia Giglio; Gianluca Caldara; Antonella Groppelli; Gianfranco Parati
Journal:  Blood Press Monit       Date:  2007-08       Impact factor: 1.444

9.  Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring.

Authors:  Anil K Pareek; Franz H Messerli; Nitin B Chandurkar; Shruti K Dharmadhikari; Anil V Godbole; Prasita P Kshirsagar; Manish A Agarwal; Kamal H Sharma; Shyam L Mathur; Mukund M Kumbla
Journal:  J Am Coll Cardiol       Date:  2016-02-02       Impact factor: 24.094

10.  Masked hypertension in diabetes mellitus: treatment implications for clinical practice.

Authors:  Stanley S Franklin; Lutgarde Thijs; Yan Li; Tine W Hansen; José Boggia; Yanping Liu; Kei Asayama; Kristina Björklund-Bodegård; Takayoshi Ohkubo; Jørgen Jeppesen; Christian Torp-Pedersen; Eamon Dolan; Tatiana Kuznetsova; Katarzyna Stolarz-Skrzypek; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Jan Filipovsky; Yutaka Imai; Jiguang Wang; Hans Ibsen; Eoin O'Brien; Jan A Staessen
Journal:  Hypertension       Date:  2013-03-11       Impact factor: 10.190

View more
  2 in total

1.  The prevalence of masked hypertension and masked uncontrolled hypertension in relation to overweight and obesity in a nationwide registry in China.

Authors:  Jia-Hui Xia; Dong-Yan Zhang; Yuan-Yuan Kang; Qian-Hui Guo; Yi-Bang Cheng; Jian-Feng Huang; Qi-Fang Huang; Wei Zhang; Li-Juan Zhang; Yu Dou; Yan-Lun Su; Hua-Ling Liu; Mei-Sheng Zheng; Xin-Juan Xu; Jian-Jun Mu; Yan Li; Ji-Guang Wang
Journal:  Hypertens Res       Date:  2022-09-14       Impact factor: 5.528

Review 2.  Pseudo and resistant hypertension: A chaotic perspective.

Authors:  Heitor Moreno
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-04-25       Impact factor: 2.885

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.